{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "24366736",
  "DateCompleted": {
    "Year": "2014",
    "Month": "10",
    "Day": "28"
  },
  "DateRevised": {
    "Year": "2021",
    "Month": "10",
    "Day": "21"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2013",
        "Month": "12",
        "Day": "23"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1128/AAC.01746-13"
    ],
    "Journal": {
      "ISSN": "1098-6596",
      "JournalIssue": {
        "Volume": "58",
        "Issue": "3",
        "PubDate": {
          "Year": "2014"
        }
      },
      "Title": "Antimicrobial agents and chemotherapy",
      "ISOAbbreviation": "Antimicrob Agents Chemother"
    },
    "ArticleTitle": "Multiple classes of antiviral agents exhibit in vitro activity against human rhinovirus type C.",
    "Pagination": {
      "StartPage": "1546",
      "EndPage": "1555",
      "MedlinePgn": "1546-55"
    },
    "Abstract": {
      "AbstractText": [
        "Human rhinovirus type C (HRV-C) is a newly discovered enterovirus species frequently associated with exacerbation of asthma and other acute respiratory conditions. Until recently, HRV-C could not be propagated in vitro, hampering in-depth characterization of the virus replication cycle and preventing efficient testing of antiviral agents. Herein we describe several subgenomic RNA replicon systems and a cell culture infectious model for HRV-C that can be used for antiviral screening. The replicon constructs consist of genome sequences from HRVc15, HRVc11, HRVc24, and HRVc25 strains, with the P1 capsid region replaced by a Renilla luciferase coding sequence. Following transfection of the replicon RNA into HeLa cells, the constructs produced time-dependent increases in luciferase signal that can be inhibited in a dose-dependent manner by known inhibitors of HRV replication, including the 3C protease inhibitor rupintrivir, the nucleoside analog inhibitor MK-0608, and the phosphatidylinositol 4-kinase III\u03b2 (PI4K-III\u03b2) kinase inhibitor PIK93. Furthermore, with the exception of pleconaril and pirodavir, the other tested classes of HRV inhibitors blocked the replication of full-length HRVc15 and HRVc11 in human airway epithelial cells (HAEs) that were differentiated in the air-liquid interface, exhibiting antiviral activities similar to those observed with HRV-16. In summary, this study is the first comprehensive profiling of multiple classes of antivirals against HRV-C, and the set of newly developed quantitative HRV-C antiviral assays represent indispensable tools for the identification and evaluation of novel panserotype HRV inhibitors."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Gilead Sciences, Foster City, California, USA."
          }
        ],
        "LastName": "Mello",
        "ForeName": "Chris",
        "Initials": "C"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Aguayo",
        "ForeName": "Esmeralda",
        "Initials": "E"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Rodriguez",
        "ForeName": "Madeleine",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Lee",
        "ForeName": "Gary",
        "Initials": "G"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Jordan",
        "ForeName": "Robert",
        "Initials": "R"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Cihlar",
        "ForeName": "Tomas",
        "Initials": "T"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Birkus",
        "ForeName": "Gabriel",
        "Initials": "G"
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Antimicrob Agents Chemother",
    "NlmUniqueID": "0315061",
    "ISSNLinking": "0066-4804"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antiviral Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Isoxazoles"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Oxadiazoles"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Oxazoles"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Piperidines"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Pyridazines"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Pyrrolidinones"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "RNA, Viral"
    },
    {
      "RegistryNumber": "107355-76-0",
      "NameOfSubstance": "Win 56291"
    },
    {
      "RegistryNumber": "47E5O17Y3R",
      "NameOfSubstance": "Phenylalanine"
    },
    {
      "RegistryNumber": "9H4570Q89D",
      "NameOfSubstance": "pleconaril"
    },
    {
      "RegistryNumber": "BML697718K",
      "NameOfSubstance": "pirodavir"
    },
    {
      "RegistryNumber": "HG18B9YRS7",
      "NameOfSubstance": "Valine"
    },
    {
      "RegistryNumber": "M351LCX45Y",
      "NameOfSubstance": "Tubercidin"
    },
    {
      "RegistryNumber": "QRR62J6WEF",
      "NameOfSubstance": "7-deaza-2'-C-methyladenosine"
    },
    {
      "RegistryNumber": "RGE5K1Q5QW",
      "NameOfSubstance": "rupintrivir"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "Antiviral Agents"
    },
    {
      "QualifierName": [
        "drug therapy",
        "virology"
      ],
      "DescriptorName": "Common Cold"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Dose-Response Relationship, Drug"
    },
    {
      "QualifierName": [],
      "DescriptorName": "HeLa Cells"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "In Vitro Techniques"
    },
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "Isoxazoles"
    },
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "Oxadiazoles"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Oxazoles"
    },
    {
      "QualifierName": [
        "analogs & derivatives"
      ],
      "DescriptorName": "Phenylalanine"
    },
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "Piperidines"
    },
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "Pyridazines"
    },
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "Pyrrolidinones"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "RNA, Viral"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Replicon"
    },
    {
      "QualifierName": [
        "drug effects",
        "genetics"
      ],
      "DescriptorName": "Rhinovirus"
    },
    {
      "QualifierName": [
        "analogs & derivatives",
        "pharmacology"
      ],
      "DescriptorName": "Tubercidin"
    },
    {
      "QualifierName": [
        "analogs & derivatives"
      ],
      "DescriptorName": "Valine"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Virus Replication"
    }
  ]
}